Fresenius Kabi launches Methocarbamol Injection in US for acute musculoskeletal conditions

Fresenius Kabi, the global German healthcare company, has unveiled Methocarbamol Injection, USP in the United States, marking a significant expansion of its anesthesia and analgesia portfolio. The 100 mg per mL, 10 mL vial presentation is designed to assist in relieving the discomfort associated with acute, painful musculoskeletal conditions.

This new injectable treatment, which can be administered intravenously or intramuscularly, aims to provide essential relief to patients suffering from musculoskeletal issues, supplementing rest, physical therapy, and other traditional treatments.

Expansion of anesthesia and analgesia portfolio

John Ducker, president and CEO of Fresenius Kabi USA, expressed the company’s enthusiasm about the launch, stating, “We are pleased to expand our anesthesia and analgesia portfolio with the introduction of Methocarbamol Injection, a medication that can provide relief for people with acute, painful musculoskeletal conditions.”

This move comes as part of Fresenius Kabi’s ongoing commitment to improving patient care through innovative treatments. Methocarbamol Injection, USP, is the latest addition to its growing portfolio of anesthesia and analgesia drugs. This follows the 2018 release of Omegaven, a fish oil triglyceride injectable emulsion designed to treat parenteral nutrition-associated cholestasis (PNAC) in pediatric patients.

Methocarbamol Injection details and availability

Now available in a 100 mg per 10 mL vial, Methocarbamol Injection is aimed at easing musculoskeletal discomfort in patients, offering a valuable solution to those experiencing acute pain. Fresenius Kabi is distributing this new medication to hospitals and clinics across the US, providing a vital therapeutic option for pain management in specific conditions.

Previous successful launches by Fresenius Kabi

Fresenius Kabi has demonstrated a track record of successful product launches in the US, with Omegaven standing out as a critical treatment for pediatric patients facing severe nutritional complications. The company’s portfolio continues to evolve, with Methocarbamol Injection now poised to add significant value to its analgesia offerings.